Demographic, clinical and procedural characteristics of the patients
| Variables | Value |
| Cases | 379 |
| Age, years; mean (SD) | 56.7±10.5 |
| Female (%) | 244 (64.4) |
| Smoking (%) | 68 (17.9) |
| Drinking (%) | 34 (9.0) |
| Hypertension (%) | 194 (51.2) |
| Hyperlipidaemia (%) | 46 (12.1) |
| Diabetes (%) | 42 (11.1) |
| Coronary artery disease (%) | 22 (5.8) |
| Cerebrovascular stenosis (%) | 65 (17.2) |
| Ischaemic cerebrovascular disease (%) | 31 (8.2) |
| Red cell count, ×1012/L; mean (SD) | 4.6±5.2 |
| White cell count, ×109/L; mean (SD) | 8.1±26.7 |
| Platelet count, ×109/L; mean (SD) | 242.3±61.8 |
| APTT, s; mean (SD) | 30.4±3.3 |
| INR, %; mean (SD) | 1.0±0.1 |
| Posterior circulation UIAs (%) | 58 (15.3) |
| Maximum size, mm; mean (SD) | 7.9±5.8 |
| Multiple aneurysms (%) | 78 (20.6) |
| Non-saccular aneurysms (%) | 42 (11.1) |
| Flow diverters (%) LTA | 199 (52.5) |
| ADP-MPA, %; mean (SD) | 36.6±14.0 |
| AA-MPA, %; mean (SD) | 9.8±7.7 |
| Metabolic types | |
| Ultra-fast metabolisers (%) | 5 (1.3) |
| Fast metabolisers (%) | 155 (40.9) |
| Intermediate metabolisers (%) | 169 (44.6) |
| Poor metabolisers (%) | 50 (13.2) |
AA-MPA, maximum platelet aggregation rate induced by arachidonic acid; ADP-MPA, maximum platelet aggregation rate induced by ADP; APTT, activated partial thromboplastin time; INR, international normalised ratio; LTA, light transmission aggregometry; UIAs, unruptured intracranial aneurysms.